Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma
World Journal of Surgical Oncology · 2024
DOI: 10.1186/s12957-024-03417-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Surgical Oncology, 2024. Verfasst von Hong Xiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Hainan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Sorafenib, Liver Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Although sorafenib has been consistently used as a first-line treatment for advanced hepatocellular carcinoma (HCC), most patients will develop resistance, and the mechanism of resistance to sorafenib needs further study.
Methods
Using KAS-seq technology, we obtained the ssDNA profiles within the whole genome range of SMMC-7721 cells treated with sorafenib for differential analysis. We then intersected the differential genes obtained from the analysis of hepatocellular carcinoma patients in GSE109211 who were ineffective and effective with sorafenib treatment, constructed a PPI network, and obtained hub genes. We then analyzed the relationship between the expression of these genes and the prognosis of hepatocellular carcinoma patients.
Results
In this study, we identified 7 hub ERGs (ACTB, CFL1, ACTG1, ACTN1, WDR1, TAGLN2, HSPA8) related to drug resistance, and these genes are associated with the cytoskeleton.
Conclusions
The cytoskeleton is associated with sorafenib resistance in hepatocellular carcinoma. Using KAS-seq to analyze the early changes in tumor cells treated with drugs is feasible for studying the drug resistance of tumors, which provides reference significance for future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Hainan, China.
- Department of Pharmacy, Peking University Third Hospital, 49 Huayuan North Rd, Haidian District, Beijing, 100191, China.
- Department of Pharmacology, Xinjiang Medical University, Urumqi, China.
- Department of Pharmacy, Peking University Third Hospital, 49 Huayuan North Rd, Haidian District, Beijing, 100191, China. lcchenlong@163.com.
- Peking University, Third Hospital Cancer Center, 49 Huayuan North Rd, Haidian District, Beijing, 100191, China. lcchenlong@163.com.
- Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Hainan, China. linjian@pku.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xiao, H., Chen, H., Zhang, L., Duolikun, M., Zhen, B., Kuerban, S., Li, X., Wang, Y., Chen, L., & Lin, J. (2024). Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma. World Journal of Surgical Oncology. https://doi.org/10.1186/s12957-024-03417-2
Vancouver
Xiao H, Chen H, Zhang L, Duolikun M, Zhen B, Kuerban S, et al. Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma. World Journal of Surgical Oncology. 2024. doi:10.1186/s12957-024-03417-2
BibTeX
@article{Xiao2024,
author = {Xiao, Hong and Chen, Hangyu and Zhang, Lei and Duolikun, Maimaitiyasen and Zhen, Baixin and Kuerban, Subinuer and Li, Xuehui and Wang, Yuxi and Chen, Long and Lin, Jian},
title = {Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma},
journal = {World Journal of Surgical Oncology},
year = {2024},
doi = {10.1186/s12957-024-03417-2}
}
EUVIMED